Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned
This article was originally published in The Pink Sheet Daily
Executive Summary
Development portfolio for interleukin-1ß blocker is sign of success for Novartis proof of concept R&D development model.
You may also be interested in...
CANTOS Trial Brings Unexpected CVD Promise For Novartis & Regeneron
Few expected the positive top-line results from CANTOS showing the Phase III cardiovascular disease study using canakinumab met the primary endpoint. Most want to see the full details being unveiled later in 2017.
IL-17: Pushing The Limits Of A Drug Target
A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.
Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter
The agency seeks more clinical data on canakinumab in refractory patients after an advisory committee meeting that focused on the drug's potential risks.